A5031186044- Antifungal resistance and susceptibility
- HIV/AIDS Research and Interventions
- Cystic Fibrosis Research Advances
- Nematode management and characterization studies
- Plant Disease Resistance and Genetics
- Global Maternal and Child Health
- Animal Virus Infections Studies
- Fungal Infections and Studies
- Poxvirus research and outbreaks
- HIV Research and Treatment
- Herpesvirus Infections and Treatments
- Plant Pathogenic Bacteria Studies
- Adolescent Sexual and Reproductive Health
- Antibiotic Resistance in Bacteria
- Infections and bacterial resistance
- HIV/AIDS drug development and treatment
National Health Service Scotland
2024
University of Duisburg-Essen
2012-2018
National Institute of Allergy and Infectious Diseases
2013
Background. IMPAACT P1066 is a phase I/II open-label multicenter trial to evaluate pharmacokinetics, safety, tolerability, and efficacy of multiple raltegravir formulations in human immunodeficiency virus (HIV)–infected youth.
Aspergillus fumigatus is the most prevalent filamentous fungus in respiratory tract of patients with cystic fibrosis (CF). The aim this prospective multicentre study was to investigate prevalence azole-resistant A. (ARAF) secretions from CF across Germany and characterize ARAF isolates by phenotypic molecular methods.Twelve tertiary care centres participated study. In total, 2888 961 were screened for using azole-containing agar plates. Antifungal susceptibility testing performed broth...
Background Chickenpox, a vaccine-preventable disease caused by the varicella zoster virus, generally presents with mild symptoms but can cause complications necessitating hospitalisation. In Poland, since 2009, vaccination has been obligatory for children up to 12 years of age who are particularly vulnerable infection and in their vicinity. Aim To examine burden chickenpox trends hospitalisation arising from these over time Polish population. Methods Data spanning 2006–21 were sourced...
Summary Because published reports indicate that the antibiotic colistin (COL) has antifungal properties, this study investigated in vitro activity of COL as single agent and combination with compounds voriconazole (VRC), caspofungin (CAS) amphotericin B (AMB) against Scedosporium/Pseudallescheria spp., Exophiala dermatitidis Geosmithia argillacea . In total, susceptibility was determined for 77 82 E. 17 G. isolates. The minimal inhibitory concentrations (MICs) antifungals compound were MIC...
The in vitro susceptibilities to the novel triazole isavuconazole and six other antifungal agents of a large collection Rasamsonia isolates (n = 47) belonging seven species were determined. Isavuconazole voriconazole had no activity (MIC, >32 mg/liter) against argillacea complex. echinocandins most potent drugs all tested (minimum effective concentration, ≤0.19 mg/liter).
To assess risk factors for loss to follow-up (LFU) from the IMPAACT P1041 study, an isoniazid (INH) prophylaxis study conducted in southern Africa.Infants two cohorts, human immunodeficiency virus-infected (HIV+) and HIV-exposed but non-infected (HIV-), were randomized INH or placebo 96 weeks. LFU was evaluated at week 96.Of 1351 infants, 12.9% (10.4% HIV+, 14.7% HIV-); 65% of HIV+ cohort asymptomatic. Among large household size (>6 vs. <4 members, P = 0.035) presence elder (≥55 years, 0.05)...